RX Insights from December ’25
This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. IndicationARMLUPEG (pegfilgrastim-unne) is an FDA-approved biosimilar to Neulasta (pegfilgrastim) indicated to reduce the risk of infection, as manifested by febrile neutropenia, in … RX Insights from December ’25
